UK company, Chanelle McCoy Health, has been granted ethics approval in Australia for a clinical trial investigating the effect of its synthetic CBD formulation on sleep.

The pharmaceutical company has received Ethics Approval from Bellberry Human Research Ethics Committee in Australia, for a significant Phase III Efficacy Clinical Trial for the treatment of Sleep Disturbance.

The results of the clinical trial should give key data on the efficacy of the company’s unique formulation, Ultra Pure Synthetic CBD in relation to sleep disturbance and improved sleep.

View the full article from Cannabis Health News here

Select your currency
EUR Euro
GBP Pound sterling